• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapies and medications are not effective. The individual approach to treatment could be the answer.

Cue is an intervention platform that transforms passively acquired sensor data from smartphones into customized micro-interventions to improve mental health. We analysed the best treatment for anxiety and depression - please click the next web page --fit personalized ML models for each subject using Shapley values to understand their predictors of feature and reveal distinct characteristics that can be used to predict changes in mood over time.

Predictors of Mood

Depression is among the world's leading causes of mental illness.1 However, only about half of those who have the disorder receive treatment1. To improve the outcomes, doctors must be able to recognize and treat patients with the highest likelihood of responding to specific treatments.

A customized depression treatment is one method of doing this. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit the most from certain treatments. They are using mobile phone sensors, a voice assistant with artificial intelligence, and other digital tools. With two grants awarded totaling more than $10 million, they will use these techniques to determine biological and behavioral predictors of the response to antidepressant medication and psychotherapy.

The majority of research done to so far has focused on clinical and sociodemographic characteristics. These include demographics such as gender, age and education and clinical characteristics such as symptom severity and comorbidities as well as biological markers.

Very few studies have used longitudinal data to predict mood in individuals. Many studies do not consider the fact that mood can vary significantly between individuals. Therefore, it is essential to develop methods that allow for the determination of the individual differences in mood predictors and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can identify distinct patterns of behavior and emotions that vary between individuals.

In addition to these modalities, the team also developed a machine-learning algorithm to model the dynamic predictors of each person's depressed mood. The algorithm combines the individual characteristics to create a unique "digital genotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, a psychometrically validated scale for assessing severity of symptom. However the correlation was tinny (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

Depression is one of the most prevalent causes of disability1, but it is often not properly diagnosed and treated. In addition, a lack of effective treatments and stigma associated with depressive disorders prevent many from seeking treatment.

To aid in the development of a personalized treatment, it is crucial to identify predictors of symptoms. However, current prediction methods are based on the clinical interview, which is not reliable and only detects a tiny variety of characteristics associated with depression.2

Using machine learning to blend continuous digital behavioral phenotypes captured by smartphone sensors and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory CAT-DI) with other predictors of severity of symptoms could improve the accuracy of diagnosis and treatment efficacy for depression. Digital phenotypes are able to capture a large number of unique behaviors and activities, which are difficult to capture through interviews, and allow for continuous and high-resolution measurements.

The study comprised University of California Los Angeles students with moderate to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and depression treatment in pregnancy program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical treatment in accordance with their severity of depression. Patients who scored high on the CAT-DI of 35 or 65 were allocated online support with an online peer coach, whereas those with a score of 75 patients were referred to psychotherapy in-person.

At baseline, participants provided an array of questions regarding their personal demographics and psychosocial characteristics. These included age, sex education, work, and financial situation; whether they were partnered, divorced or single; their current suicidal ideas, intent or attempts; and the frequency at which they drank alcohol. The CAT-DI was used for assessing the severity of depression-related symptoms on a scale ranging from zero to 100. The CAT-DI test was performed every two weeks for those who received online support, and weekly for those who received in-person support.

Predictors of Treatment Response

Research is focusing on personalized treatment for depression. Many studies are aimed at finding predictors that can aid clinicians in identifying the most effective medications to treat each individual. In particular, pharmacogenetics identifies genetic variants that determine how to treat anxiety and depression without medication the body metabolizes antidepressants. This allows doctors to select medications that are likely to be most effective for each patient, while minimizing the time and effort in trials and errors, while eliminating any side effects that could otherwise slow advancement.

Another promising approach is to develop prediction models that combine the clinical data with neural imaging data. These models can be used to determine which variables are the most predictive of a particular outcome, such as whether a medication can help with symptoms or mood. These models can be used to predict the response of a patient to a treatment, which will help doctors to maximize the effectiveness.

A new generation employs machine learning methods such as supervised and classification algorithms such as regularized logistic regression, and tree-based methods to integrate the effects of multiple variables to improve the accuracy of predictive. These models have been demonstrated to be effective in predicting the outcome of treatment like the response to antidepressants. These approaches are becoming more popular in psychiatry and will likely become the standard of future treatment.

In addition to prediction models based on ML research into the mechanisms that cause depression is continuing. Recent research suggests that the disorder is connected with dysfunctions in specific neural circuits. This suggests that individual depression treatment plan cbt treatment will be based on targeted treatments that target these circuits in order to restore normal function.

One method of doing this is to use internet-based interventions that offer a more personalized and customized experience for patients. One study found that a web-based program improved symptoms and led to a better quality life for MDD patients. Furthermore, a randomized controlled trial of a personalized approach to treating depression showed steady improvement and decreased adverse effects in a large number of participants.

Predictors of Side Effects

A major obstacle in individualized chronic depression treatment treatment involves identifying and predicting which antidepressant medications will cause the least amount of side effects or none at all. Many patients experience a trial-and-error method, involving various medications prescribed until they find one that is effective and tolerable. Pharmacogenetics offers a new and exciting method of selecting antidepressant medications that is more effective and specific.

Many predictors can be used to determine the best antidepressant to prescribe, such as gene variations, phenotypes of patients (e.g. gender, sex or ethnicity) and comorbidities. However, identifying the most reliable and accurate factors that can predict the effectiveness of a particular treatment is likely to require randomized controlled trials of considerably larger samples than those typically enrolled in clinical trials. This is due to the fact that it can be more difficult to detect the effects of moderators or interactions in trials that contain only one episode per participant instead of multiple episodes over a period of time.

Additionally the prediction of a patient's response will likely require information about the comorbidities, symptoms profiles and the patient's subjective experience of tolerability and effectiveness. At present, only a few easily assessable sociodemographic and clinical variables are believed to be reliably associated with response to MDD like gender, age, race/ethnicity and SES, BMI, the presence of alexithymia and the severity of depressive symptoms.

There are many challenges to overcome in the use of pharmacogenetics to treat depression. It is crucial to have a clear understanding and definition of the genetic mechanisms that cause depression, and a clear definition of an accurate indicator of the response to treatment. Additionally, ethical issues such as privacy and the ethical use of personal genetic information, should be considered with care. Pharmacogenetics can be able to, over the long term reduce stigma associated with mental health treatments and improve the quality of holistic treatment for depression. But, like all approaches to psychiatry, careful consideration and planning is necessary. At present, the most effective course of action is to provide patients with an array of effective depression medications and encourage them to speak freely with their doctors about their experiences and concerns.